• Blok narracyjny
• XML
• JSON
• TTL

: PsoriasisActiveSubstance - XML Representation

Active as of 2024-09-17

Raw xml | Download

<ValueSet xmlns="http://hl7.org/fhir">
  <id value="PLSMPLPsoriasisActiveSubstance"/>
  <meta>
    <profile
             value="https://ezdrowie.gov.pl/fhir/StructureDefinition/PLSMPLAdminValueSet"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ValueSet PLSMPLPsoriasisActiveSubstance</b></p><a name="PLSMPLPsoriasisActiveSubstance"> </a><a name="hcPLSMPLPsoriasisActiveSubstance"> </a><a name="PLSMPLPsoriasisActiveSubstance-pl-PL"> </a><ul><li>Include these codes as defined in <a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html"><code>https://ezdrowie.gov.pl/fhir/CodeSystem/PLActiveSubstanceCodeCodeSystem</code></a><table class="none"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-adalimumab">adalimumab</a></td><td>Adalimumab (dostępny w terapii pacjentów od 4 r.ż.)</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-etanercept">etanercept</a></td><td>Etanercept (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-infliksymab">infliksymab</a></td><td>Infliksymab</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-iksekizumab">iksekizumab</a></td><td>Iksekizumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-sekukinumab">sekukinumab</a></td><td>Sekukinumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-ustekinumab">ustekinumab</a></td><td>Ustekinumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-ryzankizumab">ryzankizumab</a></td><td>Ryzankizumab</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-guselkumab">guselkumab</a></td><td>Guselkumab</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-certolizumab_pegol">certolizumab_pegol</a></td><td>Certolizumab pegol</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-tyldrakizumab">tyldrakizumab</a></td><td>Tyldrakizumab</td></tr><tr><td><a href="CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-bimekizumab">bimekizumab</a></td><td>Bimekizumab</td></tr></table></li></ul></div>
  </text>
  <url
       value="https://ezdrowie.gov.pl/fhir/ValueSet/PLSMPLPsoriasisActiveSubstance"/>
  <version value="25.0.0"/>
  <name value="PLSMPLPsoriasisActiveSubstance"/>
  <title value="PsoriasisActiveSubstance"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2024-09-17T15:37:37+02:00"/>
  <publisher value="CeZ"/>
  <contact>
    <name value="CeZ"/>
    <telecom>
      <system value="url"/>
      <value value="https://ezdrowie.gov.pl"/>
    </telecom>
  </contact>
  <description
               value="Słownik dostępnych substancji czynnych w programie lekowym 'Łuszczyca'"/>
  <useContext>
    <code>
      <system value="urn:oid:0.0.0.0.0"/>
      <code value="setOfValueSet"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system
                value="https://ezdrowie.gov.pl/fhir/CodeSystem/PLSMPLSetOfValueSetsCodeSystem"/>
        <code value="slowniki_substancji"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="PL"/>
      <display value="Poland"/>
    </coding>
  </jurisdiction>
  <compose>
    <include>
      <system
              value="https://ezdrowie.gov.pl/fhir/CodeSystem/PLActiveSubstanceCodeCodeSystem"/>
      <concept>
        <code value="adalimumab"/>
        <display value="Adalimumab (dostępny w terapii pacjentów od 4 r.ż.)"/>
      </concept>
      <concept>
        <code value="etanercept"/>
        <display value="Etanercept (dostępny w terapii pacjentów od 6 r.ż.)"/>
      </concept>
      <concept>
        <code value="infliksymab"/>
        <display value="Infliksymab"/>
      </concept>
      <concept>
        <code value="iksekizumab"/>
        <display
                 value="Iksekizumab (dostępny w terapii pacjentów od 6 r.ż.)"/>
      </concept>
      <concept>
        <code value="sekukinumab"/>
        <display
                 value="Sekukinumab (dostępny w terapii pacjentów od 6 r.ż.)"/>
      </concept>
      <concept>
        <code value="ustekinumab"/>
        <display
                 value="Ustekinumab (dostępny w terapii pacjentów od 6 r.ż.)"/>
      </concept>
      <concept>
        <code value="ryzankizumab"/>
        <display value="Ryzankizumab"/>
      </concept>
      <concept>
        <code value="guselkumab"/>
        <display value="Guselkumab"/>
      </concept>
      <concept>
        <code value="certolizumab_pegol"/>
        <display value="Certolizumab pegol"/>
      </concept>
      <concept>
        <code value="tyldrakizumab"/>
        <display value="Tyldrakizumab"/>
      </concept>
      <concept>
        <code value="bimekizumab"/>
        <display value="Bimekizumab"/>
      </concept>
    </include>
  </compose>
</ValueSet>